Atrophic Gastritis Predicts the Risk of Gastric Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Esophagogastroscopy (OLGA 0-Ⅰ): Surveillance endoscopies at years 3-5.

Esophagogastroscopy (OLGA II): Surveillance endoscopies at years 2-3.

Esophagogastroscopy (OLGA III-IV): Surveillance endoscopies every year.

Study summary

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Eligibility

Primary outcome measure(s)

• early gastric neoplasm — After the baseline endoscopy, participants were scheduled for surveillance endoscopies at years 3-5 for subjects with operative link on gastritis assessment (OLGA) 0-Ⅰ, at years 2-3 for subjects with OLGA II and 1 year for subjects with OLGA III-IV.
  histological diagnosis of high-grade dysplasia, and adenocarcinoma.

Trial sites (1)

More Shanghai Jiao Tong University School of Medicine trials in China